Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | COMT | P21964 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178288 | 0.77 | CA12 (0.36) | TYRDOHHKDM4ECA12CA1 | |
| SCHEMBL7640934 | 0.75 | TYR (0.53) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL9700040 | 0.72 | TYR (0.58) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL10427968 | 0.72 | AKR1B1 (0.51) | CYP3A4 | |
| SCHEMBL17128963 | 0.72 | DOHH (0.50) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL10924548 | 0.72 | TYR (0.50) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL8102332 | 0.72 | DOHH (0.54) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL9798176 | 0.71 | CYP3A4 (0.42) | CA12CA2CA9CYP3A4 | |
| SCHEMBL12949560 | 0.70 | TYR (0.61) | TYRDOHHKDM4ECOMTCA12 | |
| SCHEMBL10613124 | 0.70 | TYR (0.61) | TYRDOHHKDM4ECOMTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687298-B1 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | APOTEX INC (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-8097624-B2 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. (CA) | 2012-01-17 | — | — | US | disclosed |
| US-20090170850-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. | 2009-07-02 | — | — | US | disclosed |
| US-7410985-B2 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | APOTEX INC. (CA) | 2008-08-12 | — | — | US | disclosed |
| EP-1474396-B9 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1687298-A4 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | APOTEX INC (CA) | 2007-10-17 | — | — | EP | disclosed |
| EP-1474396-B1 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070082904-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention | APOTEX INC. (CA) | 2007-04-12 | — | — | US | disclosed |
| EP-1687298-A1 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | Apotex Inc. (CA) | 2006-08-09 | — | — | EP | disclosed |
| EP-1474396-A4 | N-SUBSTITUTED3-HYDROXY-4-PYRIDINONES AND PHARMACEUTICALS CONTAINING THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2001017497-A1 | DEPIGMENTING COMPOSITIONS | GHISALBERTI CARLO (BR) | 2001-03-15 | — | — | WO | disclosed |
| US-6080766-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A HYDROXYPYRROLIDONE COMPOUND TO SUPPRESS THE FORMATION OF COLLAGEN-LIKE SUBSTANCES OR BIOSYNTHESIS OF PROCOLLAGEN | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-06-27 | — | — | US | disclosed |
| US-6046219-A | ADMINISTERING TO THE PATIENT FOR TREATING THE CONDITIONS MEDIATED BY COLLAGEN FORMATION TOGETHER WITH CELL PROLIFERATION A HYDROXYPYRIDINE DERIVATIVE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5965585-A | SUPPRESSING FORMATION OF COLLAGEN AND COLLAGEN-LIKE SUBSTANCES OR BIOSYNTHESIS OF PROCOLLAGEN IN LIVING SYSTEMS BY ADMINISTERING A HYDROXYPYRIDONE COMPOUND ENZYME INHIBITOR OF PROTEIN HYDROXYLASE; ANTISCARRING AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5965586-A | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5849587-A | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5789426-A | SUPPRESSION FORMATION OF COLLAGEN | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0614378-A1 | TECHNETIUM-99 m COMPLEXES WITH N-SUBSTITUTED 3-HYDROXY-4-PYRIDINONES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-14 | — | — | EP | disclosed |
| US-5336482-A | Diagnostic scintigraphic imaging | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-08-09 | — | — | US | disclosed |
| WO-1993010822-A1 | TECHNETIUM-99 m COMPLEXES WITH N-SUBSTITUTED 3-HYDROXY-4-PYRIDINONES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170850-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones | HAMP, C1S, C1R | TYR 268/4885DOHH 257/4885KDM4E 2122/4885 |
| US-20070082904-A1 | Cycloalkyl derivatives of 3-hydroxy-4-pyridinones field of the invention | HAMP, C1S, SLC40A1 | TYR 300/4885DOHH 459/4885KDM4E 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.